DiagnosTear Technologies Inc. (DTR.CN)
Canadian Sec · CAD · Healthcare · Medical Instruments & Supplies
CA$0.25 (+0.00%) as of
Key statistics
- Market cap
- 15.21M
- EPS (TTM)
- -0.1100
- Dividend yield
- 0.00%
- 52-week range
- 0.2100 – 0.8800
- Profit margin
- 0.00%
About DiagnosTear Technologies Inc.
DiagnosTear Technologies Inc., an ophthalmic company, develops and commercializes disruptive diagnostic solutions for eye diseases. It engages in the development of TeaRx Dry Eye, a CE-IVD approved test based on the TeaRx platform for the identification and monitoring of dry eye syndrome; TeaRx Red Eye for differential assessment of adenoviral conjunctivitis, herpetic keratitis, and allergic conjunctivitis; and TeaRx Tear Collector, a non-invasive collector of one microliter of tear fluid and subsequent dilution in assay buffer for downstream analytical testing. The company was formerly known as Oceanview Technologies Inc. and changed its name to DiagnosTear Technologies Inc. DiagnosTear Technologies Inc. was incorporated in 2023 and is based in Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Headquarters
- Vancouver, BC, Canada
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.